You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,383,954


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,383,954
Title:Methods of inducing responsiveness to anti-angiogenic agent
Abstract: The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a F AS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.
Inventor(s): Leubitz; Andrea Rachel (Efrat, IL), Sher; Naamit (Rechovot, IL), Feige; Erez (Hemed, IL), Breitbart; Eyal (Hashmonaim, IL)
Assignee: Vascular Biogenics Ltd. (Modi\'in, IL)
Application Number:15/607,083
Patent Claims:1. A method of reducing the size, slowing the growth, or stopping the growth of a tumor in a subject in need thereof comprising: (i) administering to the subject a vector which consists of the nucleotide sequence set forth in SEQ ID NO: 19, wherein the responsiveness of the subject to a VEGF antagonist is increased after the administration of the vector, and (ii) administering a VEGF antagonist to the subject, wherein the tumor size or tumor growth in the subject is reduced after administration of the VEGF antagonist.

2. The method of claim 1, wherein the VEGF antagonist is an anti-VEGF antibody or a VEGF binding molecule.

3. The method of claim 2, wherein the anti-VEGF antibody is a monoclonal antibody, a humanized antibody, a human antibody, a single chain antibody, or a chimeric antibody.

4. The method of claim 3, wherein the anti-VEGF antibody is bevacizumab.

5. The method of claim 1, wherein the vector is administered at an effective amount of about 1.times.10.sup.11 virus particles to about 1.times.10.sup.14 virus particles.

6. The method of claim 4, wherein the bevacizumab is administered at an effective amount of about 1 mg/kg to about 15 mg/kg.

7. The method of claim 4, wherein the vector is administered at an effective amount of about 1.times.10.sup.12 to about 1.times.10.sup.13 virus particles and bevacizumab is administered at an effective amount of 5 mg/kg to 15 mg/kg.

8. The method of claim 2, wherein the VEGF antagonist is selected from the group consisting of bevacizumab, ranibizumab, VGX-100, r84, aflibercept, IMC-18F1, IMC-1C11, and ramucirumab.

9. The method of claim 2, wherein the vector is repeatedly administered.

10. The method of claim 9, wherein the vector is repeatedly administered once in about 2 weeks to once in about 6 months.

11. The method of claim 4, wherein the bevacizumab is repeatedly administered.

12. The method of claim 11, wherein the bevacizumab is repeatedly administered once in about 7 days to once in about 6 months.

13. The method of claim 4, wherein the vector is repeatedly administered every 2 months and the bevacizumab is repeatedly administered every 2 weeks.

14. The method of claim 1, wherein the tumor is a metastatic tumor.

15. A method of treating a disease or condition associated with tumor in a subject in need thereof comprising: (i) administering to the subject a vector which consists of the nucleotide sequence set forth in SEQ ID NO: 19, wherein the responsiveness of the subject to a VEGF antagonist is increased after the administration of the vector, and (ii) administering a VEGF antagonist to the subject, wherein the disease or condition in the subject is treated after administration of the VEGF antagonist.

16. The method of claim 15, wherein the tumor of the subject is progressed after administration of the vector.

17. The method of claim 15, wherein the VEGF antagonist is selected from the group consisting of bevacizumab, ranibizumab, VGX-100, r84, aflibercept, IMC-18F1, IMC-1C11, and ramucirumab.

18. The method of claim 15, wherein the tumor is associated with Leukemia, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, breast cancer, ovarian cancer, lung cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, small-cell lung tumors, primary brain tumors, stomach cancer, colon cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, papillary thyroid cancer, neuroblastoma, neuroendocrine cancer, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, cervical cancer, endometrial cancer, adrenal cortical cancer, prostate cancer, Mullerian cancer, ovarian cancer, peritoneal cancer, fallopian tube cancer, uterine papillary serous carcinoma, metastatic colorectal cancer (mCRC), advanced nonsquamous non-small cell lung cancer (NSCLC), metastatic renal cell carcinoma (mRCC), or glioblastoma multiforme (GBM).

Details for Patent 10,383,954

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 ⤷  Try a Trial 2033-02-04
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 06/30/2006 ⤷  Try a Trial 2033-02-04
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 08/10/2012 ⤷  Try a Trial 2033-02-04
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 10/13/2016 ⤷  Try a Trial 2033-02-04
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.